Curis, Inc. to Release Third Quarter 2012 Financial Results and Hold Conference Call on November 6, 2012

Published: Oct 30, 2012

LEXINGTON, Mass., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its third quarter financial results on Tuesday, November 6, 2012, before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) Erivedge™ (vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech, (ii) CUDC-101, CUDC-907 and Debio 0932 (iii) its financial results as of and for the three- and nine-month periods ended September 30, 2012, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

Back to news